Pulse Biosciences (NASDAQ:PLSE) Shares Down 6.5% – Here’s Why

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) were down 6.5% during trading on Friday . The company traded as low as $22.78 and last traded at $23.4450. Approximately 63,161 shares were traded during trading, a decline of 82% from the average daily volume of 351,048 shares. The stock had previously closed at $25.08.

Pulse Biosciences News Roundup

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Business update highlighted strong clinical/operational results for the nPulse™ system — headline procedural success rates of 100% freedom from AF at 6 months and 96% procedural success in another cohort, which supports the commercial and clinical potential of the nanosecond PFA platform. Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
• Positive Sentiment: Pulse beat EPS expectations (reported loss of $0.26 vs. consensus -$0.32), which reduces near-term earnings risk relative to street estimates. Investors often view an EPS beat as supportive for sentiment. Pulse Biosciences Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Management will present at the 46th Annual TD Cowen Healthcare Conference — an opportunity to increase investor visibility, refresh guidance/roadmap, and potentially catalyze interest if management provides positive commercialization updates. Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
• Neutral Sentiment: Full Q4 earnings call transcripts and reconstructions are available (Seeking Alpha, MSN); useful for investors who want management’s tone on commercialization timelines, reimbursement, and cash runway but no new headline news. Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst/market previews (e.g., Benzinga) discuss earnings potential and longer-term opportunity; these are background context rather than immediate catalysts. A Glimpse of Pulse Biosciences’s Earnings Potential
• Negative Sentiment: Revenue materially missed expectations — reported essentially flat/negative revenue versus street estimates (company reported minimal revenue vs. expected ~$0.23M), which likely drove near-term selling pressure despite the EPS beat. Pulse Biosciences Earnings & Press Release Summary
• Negative Sentiment: Insider stock sales disclosed in two filings (~$470.6k and ~$472.6k) — significant insider selling can be interpreted negatively by the market and may amplify downward pressure. Pulse Biosciences (NASDAQ:PLSE) Insider Sells $470,600.00 in Stock Pulse Biosciences (NASDAQ:PLSE) Insider Sells $472,600.00 in Stock

Analyst Upgrades and Downgrades

Several research firms have recently commented on PLSE. Mizuho set a $30.00 price objective on Pulse Biosciences in a research note on Friday, February 6th. Oppenheimer reissued an “outperform” rating and set a $30.00 price target on shares of Pulse Biosciences in a report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $30.00.

Pulse Biosciences Trading Down 10.5%

The firm has a 50 day moving average of $16.21 and a 200-day moving average of $16.03. The company has a market cap of $1.52 billion, a P/E ratio of -19.81 and a beta of 1.77.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06. The company had revenue of ($0.09) million for the quarter, compared to analysts’ expectations of $0.23 million.

Insider Activity

In related news, insider Kevin Patrick Danahy sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $23.63, for a total value of $472,600.00. Following the sale, the insider directly owned 43,298 shares in the company, valued at approximately $1,023,131.74. The trade was a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 80,000 shares of company stock valued at $1,876,200 over the last quarter. Insiders own 74.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. AlphaQuest LLC increased its stake in Pulse Biosciences by 184.5% during the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after acquiring an additional 5,748 shares during the last quarter. Westside Investment Management Inc. boosted its holdings in shares of Pulse Biosciences by 10.5% in the 2nd quarter. Westside Investment Management Inc. now owns 64,290 shares of the company’s stock worth $970,000 after purchasing an additional 6,135 shares during the period. Argo Wealth Advisory LLC bought a new position in shares of Pulse Biosciences during the 4th quarter valued at approximately $387,000. Quotient Wealth Partners LLC purchased a new stake in Pulse Biosciences during the 4th quarter valued at $218,000. Finally, FourThought Financial Partners LLC bought a new stake in Pulse Biosciences in the third quarter worth $355,000. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.